ATC code A08

ATC codes

A Alimentary tract and metabolism

A01 Stomatological preparations

A02 Drugs for acid related disorders

A03 Drugs for functional gastrointestinal disorders

A04 Antiemetics and antinauseants

A05 Bile and liver therapy

A06 Drugs for constipation

A07 Antidiarrheals, intestinal anti-inflammatory/anti-infective agents

A08 Antiobesity preparations, excluding diet products

A09 Digestives, including enzymes

A10 Drugs used in diabetes

A11 Vitamins

A12 Mineral supplements

A13 Tonics

A14 Anabolic agents for systemic use

A15 Appetite stimulants

A16 Other alimentary tract and metabolism products

ATC code A08 Antiobesity preparations, excluding diet products is a therapeutic subgroup of the Anatomical Therapeutic Chemical Classification System, a system of alphanumeric codes developed by the WHO for the classification of drugs and other medical products. Subgroup A08 is part of the anatomical group A Alimentary tract and metabolism.^[1]

Codes for veterinary use (ATCvet codes) can be created by placing the letter Q in front of the human ATC code: QA08...^[2] ATCvet codes without corresponding human ATC codes are cited with the leading Q in the following list.

National issues of the ATC classification may include additional codes not present in this list, which follows the WHO version.

A08A Antiobesity preparations, excluding diet products

A08AA Centrally acting antiobesity products

A08AA01 Phentermine

A08AA02 Fenfluramine

A08AA03 Amfepramone

A08AA04 Dexfenfluramine

A08AA05 Mazindol

A08AA06 Etilamfetamine

A08AA07 Cathine

A08AA08 Clobenzorex

A08AA09 Mefenorex

A08AA10 Sibutramine

A08AA11 Lorcaserin

A08AA56 Ephedrine, combinations

A08AA62 Bupropion and naltrexone

A08AB Peripherally acting antiobesity products

A08AB01 Orlistat

QA08AB90 Mitratapide

QA08AB91 Dirlotapide

A08AX Other antiobesity drugs

A08AX01 Rimonabant

References

↑ "ATC/DDD Index 2016: code A08". WHO Collaborating Centre for Drug Statistics Methodology.
↑ "ATCvet Index 2016: code QA08". WHO Collaborating Centre for Drug Statistics Methodology.

Antiobesity agents/Anorectics (A08)

Central

Stimulants	4-Methylamphetamine^‡ Amfecloral Amfepentorex Amfepramone Aminorex^‡ Amphetamine Amphetaminil Atomoxetine Benfluorex^‡ Benzphetamine Bupropion (+naltrexone; +zonisamide^†) Cathine Cathinone Chlorphentermine Ciclazindol Clobenzorex Cloforex Clominorex Clortermine Dexfenfluramine^‡ Dextroamphetamine Dexmethylphenidate Difemetorex^‡ Dimethylcathinone Diphemethoxidine Ephedrine Ephedra^‡ Etilamfetamine Etolorex Fenbutrazate Fencamfamine Fenethylline Fenfluramine^‡ (+phentermine^‡) Fenproporex Fludorex Fluminorex Furfenorex^‡ Indanorex Khat Levopropylhexedrine Lisdexamfetamine Manifaxine Mazindol Mefenorex Methamphetamine Methylphenidate Norfenfluramine Pemoline Pentorex Phendimetrazine Phenethylamine Phenmetrazine Phentermine (+topiramate) Phenylpropanolamine Picilorex Pipradrol Prolintane Propylhexedrine Pseudoephedrine Pyrovalerone Radafaxine Reboxetine Setazindol Sibutramine^‡ Synephrine Tesofensine Viloxazine Xylopropamine Zylofuramine

Cannabinoid receptor antagonists	Drinabant^§ Ibipinabant^§ Otenabant^§ Rimonabant^‡ Rosonabant^§ Surinabant^§ Taranabant^§

Others	5-HTP Galactomannan Guar gum Glucomannan L-DOPA L-Phenylalanine L-Tryptophan L-Tyrosine Lorcaserin Lu AA-33810 Metformin Naltrexone Naloxone Oxyntomodulin P57 Peptide YY Topiramate Yohimbine (Yohimbe) Zonisamide water

Peripheral

^#WHO-EM
^‡Withdrawn from market
Clinical trials:
- ^†Phase III
- ^§Never to phase III

This article is issued from Wikipedia - version of the Monday, January 04, 2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.